Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

AC Immune (ACIU) Invested Capital (2016 - 2025)

Historic Invested Capital for AC Immune (ACIU) over the last 11 years, with Q4 2024 value amounting to $151.2 million.

  • AC Immune's Invested Capital fell 2418.71% to $151.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $151.2 million, marking a year-over-year decrease of 2418.71%. This contributed to the annual value of $151.2 million for FY2024, which is 2418.71% down from last year.
  • According to the latest figures from Q4 2024, AC Immune's Invested Capital is $151.2 million, which was down 2418.71% from $199.4 million recorded in Q4 2023.
  • AC Immune's Invested Capital's 5-year high stood at $275.1 million during Q4 2021, with a 5-year trough of $333137.6 in Q2 2020.
  • Moreover, its 5-year median value for Invested Capital was $170.1 million (2024), whereas its average is $133.9 million.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 766.04% in 2021, then tumbled by 3126.48% in 2022.
  • AC Immune's Invested Capital (Quarter) stood at $255.5 million in 2020, then increased by 7.66% to $275.1 million in 2021, then crashed by 31.26% to $189.1 million in 2022, then grew by 5.49% to $199.4 million in 2023, then fell by 24.19% to $151.2 million in 2024.
  • Its Invested Capital was $151.2 million in Q4 2024, compared to $199.4 million in Q4 2023 and $189.1 million in Q4 2022.